Introducing the G-Rex Grants
ScaleReady has recently made a significant announcement regarding its G-Rex Grants, a program designed to support leading-edge research in cell and gene therapies. These grants are not just financial commitments; they represent a collaborative effort harnessing the expertise of multiple partners. The advancements in pediatric therapies generated by this initiative are crucial for changing lives.
Key Collaborators and Recipients
Among the notable partners in this initiative are Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH). Together with CellReady, they aim to pave the way for innovative treatments that can significantly improve outcomes for children facing serious health issues. The G-Rex Grants, totaling $375,000, have been awarded to prominent faculty members at Children's National Hospital, aiming to optimize various cell and gene therapy projects.
Dr. Patrick Hanley's Vision
Dr. Patrick Hanley, who is the Chief and Director of Cell Therapy at Children's National, has received a $100,000 grant. This funding is targeted at developing a new CAR-T cell manufacturing process using G-Rex technology. The goal is to create a process that is more nimble and cost-effective, eliminating the need for cumbersome and expensive equipment.
Innovations in T Cell Manufacturing
Dr. Michael Keller, along with Dr. Hanley, secured a joint grant of $150,000. This funding is earmarked for the refinement of Virus Specific T cell (VST) and Tumor Antigen Associated T cell (TAAT) manufacturing processes. The transition to using G-Rex 'M' series bioreactors will enhance efficiency by minimizing physical handling during production.
Targeting Pediatric Oncology
Dr. Amy Hont has received a $75,000 grant to aid in the development of closed system G-Rex manufacturing for novel cell therapy. This grant specifically focuses on enhancements for their ATTACK TAAT cell therapy, aimed at treating various solid tumors in children.
Improving Cancer Treatment with G-Rex Technology
Additionally, Dr. Conrad Russell Cruz, as a Principal Investigator, has been awarded a $50,000 grant. His project will focus on optimizing G-Rex-centric processes for manufacturing CAR-modified TAAT cells, offering new hope for treating solid tumors.
The Bigger Picture: Why This Matters
Dr. Hanley emphasized the collaborative spirit involved in these projects. Such partnerships are vital for transitioning promising therapies from research laboratories to the patients who need them. As he stated, “This effort reflects the importance of working together to move promising cell and gene therapies from the lab to the patients who need them most.”
Leadership Voices in the Field
John Wilson, CEO of Wilson Wolf, also shared his excitement about the grants. Recognizing Children’s National Hospital’s leadership in cell and gene-modified therapies, he expressed his pride in supporting such talented teams who are pushing boundaries in pediatric oncology. This collaboration underscores the importance of funding innovative research to create effective treatments for children suffering from cancer.
The G-Rex Grant Program's Impact
Since its inception, ScaleReady's G-Rex Grant Program has exceeded $40 million in no-cost product commitments aimed at advancing cell and gene therapy development. Each grant award can be as much as $300,000, but they also extend to providing recipients with exclusive access to support from a network of G-Rex Grant Partners.
New Initiatives to Accelerate Development
Recently, ScaleReady has launched another initiative, the LEAN Cell & Gene program, in collaboration with Hanson Wade. This series of events invites CGT entities to learn strategies for improving efficiency and stabilizing operations, which is critical for the ongoing success of cell therapy advancement.
Contact Information for Interested Parties
The G-Rex Grant Program is an excellent opportunity for researchers interested in advancing their work. For additional information, interested parties can contact ScaleReady at info@scaleready.com.
About ScaleReady
ScaleReady is dedicated to enhancing cell and gene-modified therapy through its G-Rex manufacturing platform, which is practical and scalable, supporting a variety of clinical trials and commercial drug products. The company's unique approach ensures that therapies are more accessible than ever before.
Frequently Asked Questions
What are the G-Rex Grants?
The G-Rex Grants are funding opportunities provided by ScaleReady aimed at supporting innovative research in cell and gene therapy, specifically for pediatric applications.
Who received the G-Rex Grants?
Key recipients include Dr. Patrick Hanley, Dr. Michael Keller, Dr. Amy Hont, and Dr. Conrad Russell Cruz, all of whom are working on various projects at Children's National Hospital.
How much funding is available through the G-Rex Grants?
The G-Rex Grant Program provides up to $300,000 per individual grant award to support various research initiatives in cell and gene therapies.
What is ScaleReady's role in the field of CGT?
ScaleReady provides a specialized G-Rex manufacturing platform that facilitates the development and scaling of cell and gene-modified therapies, benefiting over 800 organizations globally.
How can I learn more about G-Rex and its initiatives?
For more information, you can contact ScaleReady directly or visit their website to explore the G-Rex Grant Program and related initiatives.
